NUOMEDIS

Nuomedis AG is a joint-stock company under swiss law registered in Liestal Switzerland. It was founded on 4th of July 2014 by Dr. Marko Loparic and Nanosurf AG in order to focus on the development of a clinical grade device to measure the stiffness of diseased tissue and exploit the new nanomechanical cancer diagnostics applications. The mission of Nuomedis is to empower physicians around the world with the possibilities of nanomechanical tissue diagnostics and prognostics. Nuomedis develops the first clinical grade instrument which measures the nanomechanical fingerprint of cancer. Individual cancer signatures will enhance the spectrum of cancer diagnosis and prognosis, thus lead to better adjusted treatment options for patients.